OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH Circular 5/2020
DH 289/2020

21st January 2020

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Abiraterone 500mg Tablets

As part of Government's initiative to continue increasing the availability of Oncology Drugs, it is being brought to your attention that Abiraterone 500mg tablets are now available on the Government Formulary List for in-patient and out-patient use.

Abiraterone 500mg tablets can be prescribed by Consultant Oncologists for prostate cancer as per protocol 8 (Annex 1).

In view of this new introduction, the protocol of enzalutamide 40mg capsules (protocol 300) was updated accordingly as per annex (Annex 2) attached.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer

Office of the Chief Medical Officer (Health)
t +356 22992232 **e** denis.vella-baldacchino@gov.mt

8

Abiraterone 500mg Tablets

Prescriber Criteria: Consultant Oncologist

Out-patient and In-patient use:

1. Malignant Diseases

- For the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy, or
- For the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Duration of Approval:

1 year

300

Enzalutamide 40mg Capsules

Prescriber Criteria: Consultant Oncologist

Out-patient and In-patient use:

1. Malignant Diseases

To be reserved for patients who are intolerant to abiraterone, or the use of abiraterone is contraindicated, or abiraterone treatment was ineffective:

- For the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy, or
- For the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Duration of Approval:

1 year